Opioid use disorder
Drug research and approvals for opioid use disorder: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 235 studies of opioid use disorder are recruiting on ClinicalTrials.gov, and Health Canada has authorized 10 drug trials for it since 2013.
- Recruiting worldwide: 235
- Trials authorized in Canada: 10
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 235 recruiting on ClinicalTrials.gov ↗- TMS to Improve Recovery Outcomes Among Patients With Opioid Use Disorder (OUD) and Alcohol Use Disorder (AUD)NCT07171359 · Not applicable · Washington State University · starts Jun 1, 2027
- Improving Jail Response to the Overdose Crisis: A Hybrid Trial of Jail ECHO to Improve MOUD Implementation and Public…NCT07637994 · Not applicable · University of Massachusetts, Worcester · starts Jan 1, 2027
- Cortical rTMS as a Treatment for DepressionNCT05487911 · Not applicable · Baylor College of Medicine · starts Nov 1, 2026
- A Study of Cebranopadol for Opioid Withdrawal Symptoms in Adults With Chronic PainNCT07874620 · Phase 2 · Adneuris Therapeutics, Inc. · starts Oct 1, 2026
- Characterization of CB1 Receptors Using [11-C]OMAR in Opioid Use DisorderNCT07800520 · Phase 1 · Yale University · starts Oct 1, 2026
- Supporting Treatment for Opioids and Recovery Capital (STORC) - R61 PhaseNCT07787039 · Not applicable · Friends Research Institute, Inc. · starts Sep 26, 2026
- VK4-116 Phase I Study With Food-EffectNCT06808932 · Phase 1 · National Institute on Drug Abuse (NIDA) · starts Sep 25, 2026
- How Does the Opioid System Shape Stress and Social Behaviour in Men and Women and What Role Does Childhood…NCT07778511 · Not applicable · Sara L. Kroll · starts Sep 24, 2026
- Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy ClinicNCT07176351 · Phase 4 · Yale University · starts Sep 23, 2026
- A Clinical Trial of Telehealth Treatment for Opioid Use DisordersNCT07362082 · Not applicable · Yale University · starts Sep 11, 2026
Trials Authorized in Canada
Newest first; search them all in Canada trials| Oct 1, 2026 | Bridge study: buprenorphine xr real-world induction, dosing, and gradual evaluationBUPRENORPHINE | DR. NAVNEET SINGH KHOSA | Pending |
| May 29, 2026 | A single-site, single arm, pilot clinical trial at vancouver general hospital to evaluate the safety, feasibility and effectiveness of restarting individuals…METHADONE | VANCOUVER COASTAL HEALTH UNIVERSITY OF BRITISH COLUMBIA | Pending |
| Dec 18, 2025 | A phase 2, randomized, double-blind, placebo-controlled study with a separate open-label cohort to evaluate the efficacy and safety of brenipatide as…BRENIPATIDE (LY3537031) / BUPRENORPHINE-NALOXONE | Eli Lilly | Ongoing |
| Sep 24, 2025 | Symptom-inhibited naloxone induction (sini) for initiating buprenorphine/naloxone and buprenorphine extended release in opioid use disorder.NALOXONE / BUPRENORPHINE / NALOXONE-BUPRENORPHINE | DR. POUYA AZAR | Ongoing |
| Oct 6, 2023 | Open-label, single arm study of psilocybin-assisted therapy for opioid use disorder: a feasibility studyPSILOCYBIN (PEX010) | FILAMENT HEALTH CORP. | Pending |
| Jul 20, 2023 | Evaluating tetrahydrocannabinol as an adjunct to opioid agonist therapy for individuals living with opioid use disorder: a phase II, placebo-controlled,…CANNABIS (DELTA-9-TETRAHYDROCANNABINOL-CANNABIDIOL) | BRITISH COLUMBIA CENTRE ON SUBSTANCE USE | Closed |
| Mar 11, 2022 | A randomised, double blind study comparing 2 maintenance dosing regimens of buprenorphine extended release subcutaneous injection (rbp 6000) in treatment…BUPRENORPHINE (RBP-6000) | Indivior | Ongoing |
| Mar 12, 2021 | A pilot study using low dose buprenorphine patches for initiation of opioid withdrawal treatment in patients with opioid use disorder to improve successful…BUPRENORPHINE | DR. DARREN R. CHRISTENSEN | Pending |
| Feb 5, 2021 | Evaluating microdosing in the emergency department: a randomized clinical trial of buprenorphine/naloxone microdosing vs. standard dosing (emed study)BUPRENORPHINE-NALOXONE | UNIVERSITY OF BRITISH COLUMBIA | Ongoing |
| Feb 4, 2020 | Comparing rapid micro-induction and induction of buprenorphine/naloxone for opioid use disorder based on the asam guidelines: a parallel group superiority…BUPRENORPHINE-NALOXONE/ HYDROMORPHONE | VANCOUVER GENERAL HOSPITAL AND UNIVERSITY OF BRITISH COLUMBIA FOUNDATION | Pending |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA